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ABSTRACT
Purpose The aim of this studywas to describe a number of electronic healthcare databases in Europe in terms of the population covered, the source
of the data captured and the availability of data on key variables required for evaluating medicine use and medicine safety during pregnancy.
Methods A sample of electronic healthcare databases that captured pregnancies and prescription data was selected on the basis of contacts
within the EUROCAT network. For each participating database, a database inventory was completed.
Results Eight databases were included, and the total population covered was 25 million. All databases recorded live births, seven captured
stillbirths and ﬁve had full data available on spontaneous pregnancy losses and induced terminations. In six databases, data were usually
available to determine the date of the woman’s last menstrual period, whereas in the remainder, algorithms were needed to establish a best
estimate for at least some pregnancies. In seven databases, it was possible to use data recorded in the databases to identify pregnancies where
the offspring had a congenital anomaly. Information on confounding variables was more commonly available in databases capturing data
recorded by primary-care practitioners. All databases captured maternal co-prescribing and a measure of socioeconomic status.
Conclusion This study suggests that within Europe, electronic healthcare databases may be valuable sources of data for evaluating
medicine use and safety during pregnancy. The suitability of a particular database, however, will depend on the research question, the type
of medicine to be evaluated, the prevalence of its use and any adverse outcomes of interest. © 2014 The Authors. Pharmacoepidemiology
and Drug Safety published by John Wiley & Sons, Ltd.
key words—electronic medical records; automated data; pregnancy; teratogens; pharmacoepidemiology
Received 19 November 2013; Revised 19 February 2014; Accepted 20 February 2014
INTRODUCTION
Medication use during pregnancy is common,1–5 and for
some classes of medicine, such as selective serotonin
reuptake inhibitors, there has been an increase in pre-
scribing over time.6 The safety of a medicine when used
during pregnancy is often unknown at the time of
market approval. This is largely due to the limited
ability of animal studies to predict human teratogenesis
and the fact that pregnant women are typically excluded
from pre-marketing randomised controlled clinical
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trials.7 The safety of medicine use during pregnancy can
therefore only be evaluated post-marketing.
Over the last 50 years, a number of surveillance
methods have been introduced including spontaneous
reporting, case–control surveillance systems and preg-
nancy exposure registries. These methods have some
limitations, however, particularly in relation to volun-
tary reporting and small sample sizes. It is these limi-
tations that have contributed to the expansion of the
use of electronic healthcare databases, containing
anonymised patient data, for evaluating the safety of
medicine use during pregnancy.
When evaluating the safety of medicine use during
pregnancy, the reliability of exposure and outcome as-
sessment are important considerations. Electronic
healthcare databases can often provide detailed data
on potential prescription drug exposure, although they
lack information on non-compliance, over-the-counter
medicine use (medicines purchased without a prescrip-
tion) and the precise timing of exposure.
In terms of outcome data, although information on
pregnancy losses may be captured, the level of detail
regarding congenital anomalies in the offspring can be
limited, and this can hamper drug safety in pregnancy
research using healthcare databases alone.8 In Europe,
the European network of population-based registries for
the epidemiological surveillance of congenital anomalies
(EUROCAT) comprises 43 registries of congenital
anomaly registrations in 23 different countries.9 These
registries capture detailed and extensive outcome infor-
mation regarding the speciﬁc types of congenital
anomaly although there may be underreporting in some
registries, and information onmedicine exposure in utero
can be limited. A study evaluating ﬁrst-trimester expo-
sure to the anticonvulsant lamotrigine and the risk of oral
clefts in the offspring was the ﬁrst study to use
EUROCAT congenital anomaly data, including the
medication exposure data routinely recorded by the
registries, to carry out a risk assessment.10 This work is
now being developed further within EUROmediCAT, a
Seventh Framework Programme study funded by the
European Commission that aims to make more system-
atic use of electronic healthcare databases in combination
with EUROCAT congenital anomaly data and build a
European system for the evaluation of medicine use in
pregnancy in relation to the risk of congenital anomalies.
This paper describes eight electronic healthcare databases
in Europe contributing to EUROmediCAT.
METHODS
A sample of electronic healthcare databases that captured
pregnancies and prescription data was selected for
this study on the basis of contacts within the
EUROCAT network. For each participating data-
base, an inventory was completed to provide infor-
mation on the population covered, the source of
the data captured and the availability of data on
key variables required for evaluating medicine use
during pregnancy as well as pregnancy outcomes.
This inventory was completed on the basis of the
data available within these databases between 2004
and 2012. Ethical and data access approvals were
obtained from the relevant governance infrastructures.
RESULTS
Seven databases were selected to participate in the
study: two in the UK,11–13 two in Italy4,14,15 and one
each in Denmark,16–18 the Netherlands3,19 and Nor-
way.20–22 Mid-way through the study, an eighth centre
from France also offered to collaborate.23 With the ex-
ception of the IADB.nl database in the Netherlands
and the Clinical Practice Research Datalink (CPRD)
in the UK, all databases involved the linkage of multi-
ple individual databases to enable the capture of preg-
nancies, prescription data and additional information
on potential confounding variables. For the remainder
of this paper, linked databases will be referred to as a
single database. A summary of the eight databases
can be found in Table 1.
Population covered
The total population covered by the eight databases
was 25 million. The Danish and Norwegian databases
covered the entire population in each country whereas
those in the Netherlands, France and Italy covered a par-
ticular region (Northern Netherlands, Haute Garonne,
Emilia-Romagna and Tuscany), and the databases in
the UK captured a sample of the population (the CPRD
capturing ~8% of the UK population and the Secure
Anonymised Information Linkage (SAIL) database
capturing approximately 40% of the population of
Wales). The potential for loss to follow-up varied
between databases with patients in Denmark, Norway
and Italy only leaving as a result of death or emigrating
from the country/region, whereas in other databases,
exit from the database could result, for example, from
the patient changing general practitioner (GP) or the
GP practice withdrawing from the database.
Exposure data
The databases in the UK captured exposure data based
on the issue of a prescription whereas all other databases
captured pharmacy dispensing data and therefore only
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those prescriptions actually dispensed (Table 1). The
majority of databases did not capture prescriptions
issued to inpatients during a hospital stay; in the UK
databases, however, some were captured if the GP
entered them following receipt of a hospital letter. In
Denmark, Norway and the Netherlands, all other pre-
scriptions were captured, including private prescrip-
tions, although a small number of rare or expensive
medicines (e.g. cancer treatments) may not have been
captured if they were dispensed at the hospital to outpa-
tients. In the French database, all prescriptions for reim-
bursed drugs were captured, regardless of whether they
had been prescribed by a GP or a specialist or had been
issued privately. In the Italian databases, prescriptions
reimbursed by the National Health Service were cap-
tured; however, the majority of private prescriptions
and prescriptions issued by a specialist to outpatients
that were dispensed at a hospital pharmacy were not
captured; the extent of hospital dispensing to outpatients
varied by product and drug class. In the UK databases,
the majority of prescriptions captured were those issued
by a GP or non-GP prescriber within primary care.
Private prescriptions and prescriptions initiated by a
specialist in a hospital outpatient department were
largely not captured, but any repeat prescriptions that
were subsequently issued by the GP were captured.
Determining the precise timing of exposure is crucial
when evaluating medicine use and safety during preg-
nancy. To do this, accurate information on the ﬁrst day
of the last menstrual period (LMP) is required. Some
databases such as those in Denmark, France and Norway
have this information or can calculate it on the basis of
gestational age at delivery for the majority of pregnan-
cies. In other databases, such as the CPRD, information
on the LMP is only sometimes recorded, and algorithms
need to be created to determine a best estimate (Table 2).
Pregnancies captured
Table 2 summarises pregnancy-related information for
each of the databases. The number of pregnancies
captured per year varied from ~2000 in the Netherlands
to ~88 000 in Denmark. This variation reﬂects the dif-
ference in the size of the source populations covered
and the types of pregnancy outcomes captured. All
databases captured live and stillborn deliveries with
the exception of the IADB.nl database where stillbirth
data were not available. Induced terminations of preg-
nancy and spontaneous pregnancy losses were captured
in all databases, except those in the Netherlands and
Emilia-Romagna (Tables 1 and 2). In the Norwegian
Medical Birth Registry, however, induced terminations
after 12weeks’ gestation were only registered when
the foetus had a congenital anomaly and spontaneous
abortions were underreported, particularly those occur-
ring before 16weeks’ gestation. Although the databases
in Wales and Tuscany captured data on pregnancy
losses, in Wales, the data are considered too sensitive
to release for research, and in Tuscany, most could not
be linked to prescription data. None of the databases
captured very early pregnancy losses that occur before
the pregnancy is clinically recognised.
Outcome data
The most frequently studied adverse pregnancy out-
come following in utero medication exposure is the
risk of major congenital anomalies. It was possible to
identify congenital anomalies in pregnancies that ended
in a live or stillbirth in all databases, with the exception
of the IADB.nl database.1 In Denmark and Norway,
congenital anomaly data could be obtained from the
national birth registers, and in Italy, they were captured
through the ‘Certiﬁcate of Delivery Assistance’. In the
CPRD, congenital anomalies could be identiﬁed from
the infants’ GP records; in Wales, they could be identi-
ﬁed from linking to the congenital anomalies database;
and in France, they could be identiﬁed from the Mother
and Child Protection Centre database and the Antenatal
Diagnostic Centre database for induced abortions. Iden-
tiﬁcation of pregnancies that were terminated following
a pre-natal diagnosis of a congenital anomaly was
largely restricted to databases that captured induced ter-
minations of pregnancy. The completeness and relia-
bility of recording of congenital anomalies, along with
the level of detail, may vary between databases and by
speciﬁc type of anomaly. Within some databases, there
is the opportunity to request additional non-coded data,
full paper medical records or to send questionnaires that
can help verify or refute diagnoses recorded in the coded
data (Table 1). In addition to information on congenital
anomalies, some databases were able to provide data on
other adverse pregnancy outcomes such as prematurity,
low or high birth weight and intrauterine growth retarda-
tion (Table 2).
Data on potential confounding variables
Table 3 summarises the availability of data on potential
confounding variables. Information on smoking status
and alcohol intake was more commonly available in
databases that captured data recorded in primary care,
1Congenital anomalies are not recorded in the database itself; however,
congenital anomalies can be identiﬁed via the North Netherlands
EUROCAT registry.
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although smoking status was available for the majority
of pregnancies ending in a live delivery in the Italian,
Danish andNorwegian databases. Data on pre-pregnancy
body mass index (BMI) were available for the major-
ity of patients in the CPRD and Tuscany databases. In
Denmark, smoking status and BMI data were not
recorded in the Patient Registry and were therefore
only available for deliveries. Limited data on smoking
and alcohol use were available in France. Data on
socioeconomic status were captured in all databases.
All databases had the potential to capture data on
additional medicines being prescribed or dispensed to
Table 3. Covariate data recorded in each of the databases
Country/region
Netherlands Denmark Norway
Italy—Emilia-
Romagna Italy—Tuscany UK Wales France
Databases IADB.nl
database
Danish
National
Birth
Registry,
Patient
Registry and
Prescription
Registry
Medical Birth
Registry of
Norway and
Prescription
Database
Emilia-Romagna
(CeDAP+ERPD)
Tuscany
(CeDAP+TPD)
General
Practice
Research
Database
Secure
Anonymised
Information
Linkage
(SAIL)
Databank
EFEMERIS
Smoking status No Yes* Yes† Yes Yes Yes Some Some‡
Alcohol
consumption
No No No No No Yes Some Some‡
Pre-pregnancy
body mass
index
No Yes* No No§ Yes Yes Some No
A measure of
socioeconomic
status
Yes** Yes†† Yes‡‡ Yes†† Yes†† Yes§§ Yes*** Yes†††
Maternal co-
prescribing
Yes Yes Yes Yes Yes Yes Yes Yes
Standard-dose
folic acid
(0.4mg)
No No Most Some Some Some—
when
prescribed
Some—when
prescribed‡‡‡
Most§§§
High-dose folic
acid (5mg)
Yes Yes Yes Yes Yes Yes Yes Most§§§
Indication for
prescribing
No Some Yes**** No No Majority Some No
Maternal co-
morbidity
No Yes Yes No No Yes Yes Some††††
Family history
of congenital
anomalies
No Some Yes Yes Yes No No For medical
terminations
Maternal
occupation
No No No Yes No No No Yes‡‡‡‡
Maternal age at
pregnancy start
Yes Yes Yes Yes Yes Yes Yes Yes
*Available for pregnancies that result in a delivery but not for those that end in a pregnancy loss.
†Available for deliveries and spontaneous abortions but not induced terminations.
‡Only for births, but data often missing (children certiﬁcates (PMI database)).
§Not for the majority of the study period but available from 2012 in CeDAP.
**Based on address/postcode.
††Based on maternal education level.
‡‡Available for all mothers registered in the MBRN and when the outcome is a termination of pregnancy owing to a congenital malformation through linkage
with the Education Database of Norway.
§§Available at a patient and practice level based on the Index of Multiple Deprivation (IMD) score, based on address and postcode.
***Based on Townsend scores and ranks and Welsh Index of Multiple Deprivation.
†††Based on maternal occupation—only available for live births.
‡‡‡All prescriptions are free in Wales so women may prefer to get a prescription rather than buy it over the counter without a prescription.
§§§Both high-dose and low-dose folic acid are available over the counter without a prescription, but both can be reimbursed, so women prefer to have them
prescribed.
****Only for reimbursed prescriptions.
††††For medical abortions and births (hypertension, diabetes, pre-eclampsia and open response).
‡‡‡‡Only for live births.
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women other than the medicine speciﬁcally being
evaluated as part of a study (maternal co-prescribing).
None of the databases, however, captured data on
medicines bought over the counter, which often includes
standard-dose 0.4mg folic acid. As a result, information
on folic acid exposure, which reduces the risk of some
congenital anomalies when taken during the pericon-
ceptional period,24,25 was often restricted to women
who received the higher 5-mg dose, which in most
countries is only available on prescription (Table 3).
Availability of data on the indication for prescribing
varied between databases. In the Norwegian prescription
database, this information was available for all medi-
cines that were reimbursed, although the level of detail
on the indication has improved since 2009. In Denmark,
some information on indication for prescribing could be
inferred from hospital diagnoses prior to prescription. In
the CPRD and SAIL, the patients’ full medical records
were available, and the indication for prescribing could
be inferred from diagnoses recorded on or around the
same date as a prescription for a particular product. No
data on the indication for prescribing were available
within the French, Italian or Dutch databases.
For the UK and Danish databases, diagnoses of
maternal comorbidities could be obtained from the
same data sources as those used for the indication of
prescribing. In Norway, however, information on
chronic diseases that the woman had before pregnancy
was recorded in the Medical Birth Registry. In France,
only data on hypertension during pregnancy, gesta-
tional diabetes and pre-eclampsia were available. No
data on maternal comorbidities were available within
the Italian or Dutch databases, although for some
chronic conditions, it may be possible to use prescrip-
tion records as proxies. Recording of a family history
of congenital anomalies was rare, and none of the
databases captured information on maternal diet.
DISCUSSION
Eight electronic healthcare databases that capture useful
information regarding medicine use during pregnancy
and a range of pregnancy outcomes have been described.
To our knowledge, this paper is the ﬁrst to provide a
comprehensive overview of the populations covered by
these databases, the types of data captured and the infor-
mation available regarding variables required for the
study of medicine use and safety during pregnancy.
Sample size considerations
One of the strengths of electronic healthcare databases
is the large number of pregnancies they capture.
Congenital anomalies are rare and arise from different
embryonic tissues and at different gestational stages.
As a consequence, the mechanism and timing of inter-
ference with embryogenesis will differ, and individual
anomalies need to be considered separately, rather
than amalgamated under a single all-embracing con-
genital anomaly category.26 In addition, the exposures
of interest may be relatively uncommon in pregnancy,
and most medicines need to be evaluated individually,
as often a ‘class effect’ cannot be assumed.7 A classic
example is the difference in teratogenicity of gluthe-
timide, which is not a major teratogen, and its derivative
thalidomide. Both of these products are glutarimides,
and both are hypnotics, yet their effects on the foetus
are dramatically different.27 The fact that congenital
anomalies as well as exposures need to be considered
at a granular rather than an aggregate level has consi-
derable implications for the required sample size for
evaluations of medicine safety in pregnancy.
The large number of pregnancies captured within
the electronic healthcare databases described in this
study and the fact that the data are routinely collected
make them a valuable tool for evaluating medicine use
during pregnancy. For medicines that are new to the
market or used to treat less prevalent conditions, how-
ever, even these large databases may be less capable
than pregnancy exposure registries of capturing an
adequate sample of exposed pregnancies during a
particular period.28,29
Exposure data
The type of exposure data captured differed between
databases, with the majority capturing prescription
dispensing data whereas the UK databases captured
all prescriptions issued. In France and Italy, only pre-
scriptions reimbursed by the health service were
captured.4,23,30 One of the strengths of electronic
healthcare databases is that prescription information
is recorded prospectively and independently, by the
prescriber or dispensing pharmacist, avoiding any ma-
ternal recall bias.31 In addition, the level of detail
available in terms of the speciﬁc product, the quantity
and daily dose prescribed tends to be high, and these
variables can often be used to calculate the duration
and, hence, timing of potential exposure. Unlike expo-
sure data obtained via a maternal interview, databases
do not provide information on non-compliance and
whether the patient took the medicine as directed.
The likelihood of exposure misclassiﬁcation may be
less of a concern for databases capturing dispensed
prescriptions than those capturing all prescriptions
issued, but, in addition, knowledge of the extent and
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type of prescriptions not captured in the database and
the impact of these is important.
In database research, exposure misclassiﬁcation can
also occur as the result of inaccurate information on
the LMP date. Only six of the eight databases
contained this information, or the gestational age at
delivery, for the majority of pregnancies. The potential
for exposure misclassiﬁcation resulting from inaccura-
cies in the LMP date will be greater for products
prescribed for short-term use (e.g. antibiotics) than for
those used long-term to treat chronic conditions.
Outcome data
In all databases, with the exception of the IADB.nl
database in the Netherlands, it was possible to identify
congenital anomalies. Unlike pregnancy exposure regis-
tries and case–control surveillance systems, which often
have the beneﬁt of review by a consultant paediatrician
or teratologist and very detailed information on the
speciﬁc congenital anomaly, electronic healthcare data-
bases often lack detail on anomalies, and researchers
may have to rely on the entry of a single medical code.
In general, databases that include links to medical birth
registries and congenital anomaly registers such as
EUROCAT are likely to contain the most detailed infor-
mation on anomalies, and it is an objective of the
EUROmediCAT project to pilot the linkage between
healthcare databases and EUROCAT congenital anom-
aly registries, where they co-exist.
An advantage of some of the databases reviewed
was their potential for capturing induced terminations
in addition to pregnancies ending in a delivery. This
is particularly beneﬁcial given that many of the more
serious congenital anomalies may be diagnosed prena-
tally and may subsequently be terminated. If such
anomalies are caused by a medicine, but not captured,
the analyses would fail to identify an increased risk.
Some databases in this review allowed the identiﬁca-
tion of clinically recognised spontaneous as well as
induced pregnancy loss, premature birth, low or high
birth weight and intrauterine growth retardation.
Potential risk factors and confounders
Surveillance systems that collect data from maternal
interviews and questionnaires have the beneﬁt of being
able to request information on additional risk factors
and potential confounders, whereas in databases, the
availability of this information can be limited. In this
review, UK primary-care databases contained the most
information on the commonly considered potential
confounding factors such as smoking status and alcohol
consumption.
CONCLUSION
Post-marketing surveillance systems are essential for
evaluating the use and safety of medicines during preg-
nancy. This study suggests that, within Europe, electronic
healthcare databases may be valuable sources of data that
can provide information on medicine utilisation patterns,
user characteristics and medicine safety during preg-
nancy. They may complement existing EUROCAT or
case–control surveillance systems, especially where no
pregnancy registry is in place. Given the potential of
databases in the ﬁeld of medication use in pregnancy,
one aspect of the EUROmediCAT study will involve
using the databases described in this paper to establish
the extent and nature of use of antiepileptic drugs,
antidiabetic medicines, asthma medicines and selective
serotonin reuptake inhibitors during pregnancy in the
different regions. It will explore the relationship between
users of the four drug groups previously mentioned and
other health behaviours and exposures in order to identify
possible confounders and effect modiﬁers in drug terato-
genicity studies. The ﬁndings of the medicine utilisation
studies will then be used to inform other aspects of
EUROmediCAT, which are focussing on linking selec-
ted electronic healthcare databases to EUROCAT con-
genital anomaly registries to study the safety of these
medicines when used during pregnancy.
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